Lynx1 Capital Management LP C4 Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $515 Million
- Q3 2025
A detailed history of Lynx1 Capital Management LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 7,098,133 shares of CCCC stock, worth $17.5 Million. This represents 3.06% of its overall portfolio holdings.
Number of Shares
7,098,133
Previous 7,098,133
-0.0%
Holding current value
$17.5 Million
Previous $10.2 Million
55.24%
% of portfolio
3.06%
Previous 3.01%
Shares
7 transactions
Others Institutions Holding CCCC
# of Institutions
109Shares Held
55.4MCall Options Held
329KPut Options Held
186K-
Soleus Capital Management, L.P. Greenwich, CT7.05MShares$17.4 Million0.95% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.24MShares$12.9 Million0.4% of portfolio
-
Morgan Stanley New York, NY4.97MShares$12.3 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.85MShares$12 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$11.2 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $121M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...